Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene
Authors:
- Keigo KosakaKKKeigo Kosaka
- Norifumi SakaiNSNorifumi Sakai
- Yuya EndoYEYuya Endo
- Yuga FukuharaYFYuga Fukuhara
- Minoru Tsuda-TsukimotoMTMinoru Tsuda-Tsukimoto
- Tatsuyuki OhtsukaTOTatsuyuki Ohtsuka
- Ichiro KinoIKIchiro Kino
- Tomohiko TanimotoTTTomohiko Tanimoto
- Naomi TakebaNTNaomi Takeba
- Masakatsu TakahashiMTMasakatsu Takahashi
- Toshiyuki KumeTKToshiyuki Kume
- 1 September 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (9) , 1495-1502
Abstract
Raloxifene is extensively glucuronidated in humans, effectively reducing its oral bioavailability (2%). It was also reported to be glucuronidated in preclinical animals, but its effects on the oral bioavailability have not been fully elucidated. In the present study, raloxifene and its glucuronides in the portal and systemic blood were monitored in Gunn rats deficient in UDP-glucuronosyltransferase (UGT) 1A, Eisai hyperbilirubinemic rats (EHBRs), which hereditarily lack multidrug resistance-associated protein (MRP) 2, and wild-type rats after oral administration. The in vitro-in vivo correlation (IVIVC) of four UGT substrates (raloxifene, biochanin A, gemfibrozil, and mycophenolic acid) in rats was also evaluated. In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine. The ratio of glucuronides to unchanged drug in systemic blood was substantially higher in EHBRs (129-fold) than in the wild-type Sprague-Dawley rats (10-fold), suggesting the excretion of raloxifene glucuronides caused by MRP2. The IVIVC of the other UGT substrates in rats displayed a good relationship, but the oral clearance values of raloxifene and biochanin A, which were extensively glucuronidated by rat intestinal microsomes, were higher than the predicted clearances using rat liver microsomes, suggesting that intestinal metabolism may be a great contributor to the first-pass effect. Therefore, evaluation of intestinal and hepatic glucuronidation for new chemical entities is important to improve their pharmacokinetic profiles.Keywords
This publication has 37 references indexed in Scilit:
- Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up ApproachDrug Metabolism and Disposition, 2011
- Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability DataDrug Metabolism and Disposition, 2010
- Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug ClearancePharmaceutical Research, 2009
- Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and RatsChemical Research in Toxicology, 2008
- Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass MetabolismThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 ModelThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1Toxicology, 2001
- PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICSBiopharmaceutics & Drug Disposition, 1996
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- The fate of gemfibrozil and its metabolites in the ratBiochemical Society Transactions, 1985